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Abstract
In resource-limited settings and in the military theater, fresh human whole blood is com-
monly transfused, but infectious risks are a concern. Sophisticated molecular testing for
potential infectious agents in the whole blood is often unavailable. To address this unmet
need, pathogen reduction technology (PRT) has been developed, and it is an effective
approach to inactivate a broad range of pathogens found in human blood. However, studies
are needed to determine if it is harmful to blood cells and whether these cells could damage
the transfused recipient, including the development of acute lung injury/acute respiratory
distress syndrome. In this study, we used a commercial PRT system to treat human whole
blood that was then transfused into immunodeficient mice, and the development of acute
lung injury was determined. In a model of transfusion-related acute lung injury (TRALI),
BALB/c SCID mice developed more robust lung injury when challenged with a MHC Class I
monoclonal antibody compared to BALB/c wild-type and NOD/SCID mice. Transfusion of
control versus Mirasol PRT-treated whole blood (25% blood volume exchange) into BALB/c
SCID mice did not produce lung injury at storage day 1. However, mild lung injury at storage
days 14 and 21 was observed without significant differences in lung injury measurements
between Mirasol PRT-treated and control groups. The mild storage-dependent acute lung
injury correlated with trends for increased levels of cell-free hemoglobin that accumulated in
both the control and Mirasol PRT-treated groups. Neutrophil extracellular traps were ele-
vated in the plasma of BALB/c SCID mice in the monoclonal antibody TRALI model, but
were not different in mice that received exchange transfusions. In conclusion, exchange
transfusion of human whole blood into immunodeficient mice produces mild lung injury that
is storage-dependent and not related to pathogen reduction treatment.
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Introduction
Although the safety of the blood supply has improved with the advent of modern transfusion
therapy, a variety of pathogens, known and unknown, continue to provide risk to transfused
recipients [1]. Current screening relies on donor questionnaires and limited laboratory testing
for specific pathogens. Molecular testing for viral pathogens has been successful in reducing
transmission risk [2], however, these tests are impractical when there is not enough time or
resources to screen for pathogens, such as the use of fresh, warm whole blood in military settings
[3–6]. Whole blood is also the most common product transfused in low-income countries [7].
A variety of pathogen-reduction technologies (PRT) have been developed to address the
potential infectious complications of transfusion therapy [8]. While these technologies can effec-
tively eliminate a variety of possible pathogens, damage to cells in the blood product may occur.
A prior study found that patients transfused with psoralen-based PRT of human platelet units
had increased cases of the acute respiratory distress syndrome (ARDS), which may have been
related to PRT-induced platelet activation [9]. These cases of ARDS are akin to transfusion-
related acute lung injury (TRALI), which is the leading cause of transfusion-related death in
many countries [10]. TRALI most commonly results from the transfusion of cognate HLA anti-
body to “primed” recipients [11], and can be modeled in mice using a MHC Class I monoclonal
antibody that produces neutrophil-, platelet-, and monocyte-dependent lung injury [12–16].
Here, we tested Mirasol1 PRT, a technology that utilizes ultraviolet light illumination of
human blood to which a photosensitizing agent, (riboflavin, vitamin B2) has been added [17].
This process creates nucleic acid modifications, which effectively inactivates a variety of patho-
gens. Our prior study in apheresis platelets showed that Mirasol PRT produced platelet activa-
tion during storage, but did not lead to the development of lung injury [18]. In this study, we
tested whether Mirasol-treated stored, human whole blood, when transfused into immunode-
ficient mice, produces lung injury. We also examined whether human whole blood treated
with Mirasol PRT induces the development of neutrophil extracellular traps (NETs) [19] after
exchange transfusion, since NETs are implicated in the pathogenesis of transfusion-related
acute lung injury (TRALI) [20, 21].
Materials and methods
Mice
BALB/c, BALB/c SCID and NOD/SCID mice (Jackson Laboratories) at 8–10 weeks of age
were used for all experiments and were housed in pathogen-free conditions.
Ethics statement
Blood was obtained from Bonfils Blood Center (Denver, CO) and the authors had no contact
with the blood donors. Thus, this study does not involve human subjects research. The study
was conducted in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. The Institutional Animal Care
and Use Committee at the University of California, San Francisco (Protocol #AN099492) as well
as by the United States Army Medical Research and Materiel Command (USAMRMC) Animal
Care and Use Review Office (ACURO) (Protocol #12229090), approved this protocol. We used
ketamine and xylazine anesthesia for all surgery and made all efforts to minimize suffering.
Human blood collection and Mirasol PRT treatment
Human whole blood was collected under an IRB (Western Institutional Review Board, Proto-
col #20090968) and USAMRMC Human Research Protection Office (HRPO, Protocol A-
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17635.2)-approved research blood collection protocol at Bonfils Blood Center (Denver, CO) in
routine 450 mL blood collection sets with citrate-phosphate-dextrose (CPD) as a preservative.
The whole blood was shipped overnight at room temperature to the University of California,
San Francisco, and Mirasol PRT treatment was done on storage day 1. Each unit of whole
blood was transferred to a Mirasol Illumination Bag (MIB) while a control unit remained in
the collection bag. Prior to treatment with the Mirasol system, thirty-five (35) mL of 500 μM
riboflavin solution was added to the test units. The Mirasol illuminator provided a UV energy
dose of 80 J/mLRBC. For untreated control units, 35 mL of normal saline was added to mimic
the dilution of the test products with riboflavin. All products were stored under standard
blood banking conditions at 4˚C until the time of experimentation. To measure cell-free
hemoglobin, 2 mL of blood was centrifuged at 2,000 g for 15 minutes and then the supernatant
was centrifuged at 3,000 g for 10 minutes. The hemoglobin of the final supernatant was mea-
sured using a HemaCue1 Plasma/Low Hb System (HemaCue, Brea, CA).
Mouse model and acute lung injury measurements
BALB/c SCID mice were primed with LPS (Escherichia coli O55:B5; Sigma-Aldrich, St. Louis,
MO, dose 0.1 mg/kg, i.p., 24 hours prior). The mice were then anesthetized with ketamine and
xylazine and an exchange transfusion was performed via a 30 gauge needle inserted into the
jugular vein. The mouse blood volume (mL) was estimated by multiplying the body weight in
grams x 7%. For example, a 25 gram mouse was estimated to have a blood volume of 1.75 mL.
We then removed 25% of this volume (438 μL) from the jugular vein over 2–3 minutes fol-
lowed immediately by transfusion of human whole blood of identical volume administered
over 2–3 minutes. The following conditions were tested: 25% estimated whole blood exchange
transfusion (untreated control vs. Mirasol PRT) on days 1, 14, and 21 of storage.
Mice were euthanized at 4 hours after transfusion consistent with the susceptible period of
TRALI development [13], and we collected blood and lungs for measurements of acute lung
injury. Extravascular lung water was measured by the gravimetric method as previously
described [13]. We measured lung vascular permeability by injecting 125I-albumin (Iso-Tex
Diagnostics, Friendswood, TX) in the jugular vein of the mice at the time of transfusion and
then measuring the ratio of radioactivity between the blood and the bloodless lung using a
gamma counter (Packard 5000 Series, Ramsey, MN) [13]. A Hemavet 950 machine (Drew Sci-
entific, Miami Lakes, FL) was used to measure hemoglobin and hematocrit in the mouse
samples.
TRALI model
We used our previously described two-event model of TRALI [12]. Briefly, after priming with
LPS (0.1 mg/kg, i.p.) 24 hours prior, mice were administered a cognate MHC Class I monoclo-
nal Ab (mAb) (ATCC 34-1-2S; H-2Kd; IgG2a, κ; 1.0 mg/kg) by jugular vein injection and
euthanized at 4 hours. In selected experiments, mice were challenged with MHC Class I mAb
alone (no LPS priming). Blood and lungs were collected to measure extravascular lung water
and lung vascular permeability. Plasma was collected in all experiments for NET analysis. In a
subset of experiments, lungs were collected in 4% paraformaldehyde or OCT for histological
analysis with hematoxylin and eosin staining, as previously described [12].
NETs ELISA
To determine the presence of neutrophil extracellular traps (NETs), we measured neutrophil
elastase (NE)–DNA complexes using a sandwich ELISA, as previously described [20, 22].
Briefly, 96-well microtiter plates were incubated with anti-mouse NE antibody (sc-9521, Santa
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Cruz Biotechnology, Inc., Dallas, TX) overnight at 4˚C. After washing wells with PBS and
blocking with 5% bovine serum albumin (BSA), 50 μL of plasma was added to wells in tripli-
cate and incubated for 2 hours at room temperature on an orbital shaker. Wells were then
washed again and incubated with 50 μL of peroxidase-conjugated anti-DNA antibody (Cell
Death Detection ELISA Kit, Roche Applied Science, Indianapolis, IN) diluted 1:100 in incuba-
tion buffer for 2 hours at room temperature. After thorough washing, 100 μL of 1-Step ABTS
reagent (Thermo Scientific, Waltham, MA) was added to each well and the plate incubated for
30 minutes at room temperature. The optical densities (OD) at 405nm and 490nm wavelengths
were measured by plate reader and the difference between the two (OD405-490) was then
applied to a standard curve derived from bronchoalveolar lavage samples obtained from mice
with acute lung injury to yield NET arbitrary units [22].
Statistical analysis
Results are reported as mean ± SEM. We used 2-tailed Student’s t and ANOVA tests to deter-
mine significance, as appropriate (GraphPad PRISM version 6.0). Log-rank testing was used
for survival analysis. P values of less than or equal to 0.05 were considered to be significant.
Results
Mirasol treatment of whole blood does not increase extracellular
hemoglobin
We measured cell-free hemoglobin in human whole blood units on storage days 1, 14 and 21.
At each time point, we compared untreated control and Mirasol PRT-treated units. Hemoglo-
bin values were not significantly different between the groups (Fig 1). There was a non-signifi-
cant overall trend for increased cell-free hemoglobin with increased storage days.
BALB/c SCID mice have increased lung injury and decreased survival in
TRALI
We used an established two-event TRALI model to challenge NOD SCID, BALB/c wild-type,
and BALB/c SCID mice. BALB/c SCID mice had increased lung injury as measured by extra-
vascular lung water and lung vascular permeability (2 to 3 fold higher) compared to NOD
SCID mice or BALB/c wild-type mice (Fig 2A and 2B). BALB/c wild-type mice had a non-sig-
nificant increase in lung injury compared to the NOD SCID mice and a small decrease in sur-
vival (Fig 2A–2C). Consistent with the severe lung injury measurements in BALB/c SCID
mice, all of the mice died by 1 hour after antibody-challenge (Fig 2C). Since an immunode-
ficient mouse strain is required for the human whole blood transfusions, we concluded that
BALB/c SCID mice are capable of producing robust lung injury and were the best choice for
these experiments.
Mirasol PRT-treated human whole blood does not produce increased
lung injury compared to untreated control blood
Human whole blood units were treated with the Mirasol PRT System or left untreated (con-
trol) and stored for 1, 14 or 21 days at 4˚C. A 25% exchange transfusion in LPS-primed BALB/
c SCID mice with Mirasol PRT-treated blood did not increase extravascular lung water (Fig
3A) or lung vascular permeability (Fig 3B) compared to exchange transfusion of untreated
control blood at any of the storage time points. However, in both groups, there was a statisti-
cally significant trend for increased mild lung injury with longer storage times (ANOVA post-
test for linear trend).
Pathogen reduction and acute lung injury
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BALB/c SCID mice challenged with either H-2d mAb alone or two-event TRALI had severe
histological lung injury with leukocyte infiltration and interstitial and alveolar edema present
(Fig 4A and 4B). In mice challenged with LPS priming plus either control or Mirasol PRT-
treated whole blood, there were no differences in histological lung injury on any of the storage
days. There is minimal to no evidence of histological lung injury in mice challenged with
whole blood on storage day 21 (Fig 4C and 4D), which is consistent with the small increases in
lung water and lung vascular permeability (Fig 3). As a measurement of systemic vascular leak-
age, BALB/c SCID mice demonstrated significant hemoconcentration with either H-2d mAb
alone or two-event TRALI (Fig 4E). LPS primed BALB/c SCID mice treated with an exchange
transfusion with either control or Mirasol-treated human whole blood had normal hematocrits
at all storage times (Fig 4F).
Neutrophil extracellular trap release is increased in TRALI
Neutrophil activation and neutrophil extracellular trap (NET) release is an important inducer
of acute lung injury. We have previously shown in BALB/c wild-type mice challenged with
TRALI that NETs are increased in the blood compartment [20]. Here, we measured plasma
NETs (by NE-DNA ELISA) in BALB/c SCID mice challenge with TRALI (± LPS priming) and
in mice challenged with LPS + either control or Mirasol-treated human whole blood. NETs
were increased in these groups, but significantly higher in the TRALI mice (Fig 5). There was
no difference in plasma NETs between the control and Mirasol-treated human whole blood
groups.
Fig 1. Cell-free hemoglobin measured in control and Mirasol treated whole blood. Mirasol PRT
treatment did not significantly change the amount of cell-free hemoglobin measured in supernatants of whole
blood bags. Between group measurements are not statistically different at 1, 14, and 21 days of blood
storage. Mean ± SEM. n = 3–6 per group. p = 0.19 for trend in hemoglobin values in control group (ANOVA).
p = 0.08 for trend in hemoglobin values in Mirasol group (ANOVA).
https://doi.org/10.1371/journal.pone.0178725.g001
Pathogen reduction and acute lung injury
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Discussion
In this experimental transfusion study, our major findings are (1) BALB/c SCID mice are
hyper-susceptible to a two-event model of TRALI and therefore a suitable immunodeficient
mouse strain to test human blood products, (2) there is no differential effect of either control
or Mirasol-treated human whole blood on lung injury, and (3) there is a mild increase in lung
injury in both groups with longer durations of whole blood storage.
Blood-borne pathogens constitute an important risk for blood transfusions worldwide.
Whereas in developed countries pathogen screening has reduced transfusion risks, there
remain challenges in the developing world and resource limited settings where testing infra-
structure may not be present. Another challenging setting for pathogen screening is within the
military where the immediate need for transfusions in trauma in forward operating settings
and lack of component blood supply necessitates the use of unscreened whole blood.
Fig 2. Lung injury and survival in mice with TRALI. LPS-primed mice challenged with MHC Class I mAb (H-2d) produced increased lung injury
measured by (A) extravascular lung water and (B) lung vascular permeability in BALB/c SCID compared to NOD SCID mice. BALB/c wild-type mice
also showed increased lung injury compared to NOD SCID mice, but significantly lower than their BALB/c SCID counterparts. Mean ± SEM. n = 4–5
per group. ****p<0.0001, ***p<0.001, *p<0.05 (ANOVA). (C) BALB/c SCID (n = 14) also showed decreased survival compared to NOD SCID
(n = 11) and BALB/c wild-type (n = 17) groups. Mean ± SEM. ****p<0.0001 vs. NOD SCID and BALB/c wild-type (Log-rank test). PRT-treated human
whole blood (pooled storage days). Mean ± SEM. *p<0.05 (ANOVA).
https://doi.org/10.1371/journal.pone.0178725.g002
Pathogen reduction and acute lung injury
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Pathogen-reduction technology offers an attractive method to reduce transfusion-related
infection risks. Several studies have shown that this technology can reduce the risk of pathogen
transmission due to contaminated blood transfusions [23, 24].
Initial studies have shown that platelet concentrate units can be treated with riboflavin and
UV light to reduce viral infections and bacteria counts without inducing acute lung injury [18,
24–26]. Although platelet activation by Mirasol treatment has been observed, the biological
effect of this activation did not lead to acute lung injury [18, 27]. However, a recent work sug-
gests that platelet transfusion clinical effectiveness might be reduced due to decreased normal
platelet function after PRT procedures [28].
We focused on Mirasol PRT-treated whole blood and tested the possible generation of lung
injury by transfusion of this treated blood. As a generalized indicator of whole blood quality,
we measured free hemoglobin values in treated and untreated blood bags after storage. Our
results revealed that Mirasol PRT did not induce more hemolysis compared to untreated con-
trol samples.
We utilized mice that were susceptible to lung injury in a well-established model of TRALI.
Previously, we used NOD SCID immunodeficient mice that, despite lacking T or B cells and
having impaired myeloid cell functions, develop moderate levels of lung injury in the TRALI
model. BALB/c SCID mice share the severe immunodeficiency mutation with NOD SCID
mice, which reduces humoral and cellular immunity, but BALB/c SCID mice have normal
myeloid lineages, including neutrophils, which are key mediators of lung injury in TRALI.
Mice with the same SCID mutation have previously been shown to be more sensitive to lung
injury than their wild-type counterparts [29] due to the lack of CD4+ regulatory T cells and
dendritic cells [30]. BALB/c SCID mice showed robust lung edema and permeability compared
to either BALB/c wild-type or NOD SCID mice, which makes this model ideal to test possible
TRALI induced by human blood transfusion.
Fig 3. Lung injury measurements in control or Mirasol treated blood transfused into BALB/c SCID mice. LPS priming plus a 25% exchange
transfusion using Mirasol PRT-treated human whole blood stored for 1 (n = 9), 14 (n = 21), or 21 (n = 13) days versus untreated control human whole
blood stored for 1 (n = 13), 14 (n = 23), or 21 (n = 11) days did not generate significant differences in extravascular lung water (A) or lung vascular
permeability (B) between the two groups (all storage times non-significant control vs. Mirasol). However, extravascular lung water and lung vascular
permeability increased with blood storage time independent of Mirasol PRT treatment. For extravascular lung water, p<0.01 for trend in both Mirasol
and control groups. For lung vascular permeability, p<0.01 for trend in Mirasol group and p = 0.11 for trend in control group (ANOVA). Mean ± SEM.
https://doi.org/10.1371/journal.pone.0178725.g003
Pathogen reduction and acute lung injury
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In this work, we studied the safety of Mirasol PRT treatments applied to whole blood units
and their relation to acute lung injury. The use of Mirasol treatment in human whole blood
before transfusing it into BALB/c SCID mice did not increase lung edema or lung permeability
compared with the untreated control blood. Our study found that blood storage time affects
lung injury parameters in a Mirasol PRT treatment-independent fashion. Longer storage time
showed a significant trend for increased extravascular lung water and lung vascular permeabil-
ity. However, no histologic differences were noted, nor was there evidence of significant hemo-
concentration suggestive of systemic vascular leak. Finally, we observed that blood treatment
before transfusion did not differentially affect NET production. These data indicate that
although there are measurable increases in lung injury with longer storage times using sensi-
tive techniques, these effects may be subclinical.
Clinical outcome studies examining the effects of storage lesion, particularly in packed red
blood cells, have produced conflicting results. A meta-analysis in 2012 suggested that use of
older stored blood was associated with a 16% increase in risk of death [31]. However, three
Fig 4. Representative lung histology and hematocrit values. H&E staining on lung sections from (A) BALB/c SCID mice + H-2d mAb, (B) BALB/c
SCID mice + LPS priming + H-2d mAb, (C) BALB/c SCID mice + LPS priming and a 25% exchange transfusion using control human whole blood
(storage day 21), and (D) BALB/c SCID mice + LPS priming and a 25% exchange transfusion using Mirasol-PRT treated human whole blood (storage
day 21). Extensive lung injury (interstitial and alveolar edema, leukocyte infiltration) is observed in the TRALI groups (A, B), but no lung injury is
detectable in either group of mice transfused with human whole blood (C, D). 20x magnification. (E) Hematocrit values in blood samples obtained from
controls, TRALI, and (F) human whole blood challenged animals. Hemoconcentration is observed with TRALI, but not in the other groups.
Mean ± SEM. ****p<0.0001, **p<0.01 (ANOVA).
https://doi.org/10.1371/journal.pone.0178725.g004
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recent randomized controlled trials showed no difference between short-term storage versus
longer storage of transfused blood in 90-day mortality for critically ill patients, in-hospital
mortality for hospitalized patients, or Multiple Organ Dysfunction Score for those patients
undergoing cardiac surgery [32–34]. Our study found a mild increase in lung injury with pro-
longed storage of human whole blood, but it would be very rare for whole blood to ever be
transfused at>2 weeks of storage time [35].
Our work has limitations. Our 4-hour endpoint might not be sufficient time to observe lon-
ger-term effects induced by whole blood transfusion. However, TRALI is clinically defined as
acute lung injury within 6 hours of transfusion, and most cases occur within 1–2 hours after
transfusion [36]. Therefore, we believe that a 4-hour period of observation is sufficient. Also,
transfusions using unscreened whole blood are rare in developed settings and limited to very
specific conditions; this fact limits the scope of our study. Nevertheless, resource-limited set-
tings and critical situations, such as in the military, require a readily available blood supply
from healthy donors. Thus, we consider that this work remains relevant for certain clinical
situations.
As a final conclusion, we demonstrated that although stored whole blood storage might
induce mild lung injury, these effects are independent of PRT treatment. Our work
Fig 5. Presence of NETs in plasma after TRALI or human whole blood transfusion. Plasma NETs in
BALB/c SCID mice challenged with no intervention, LPS priming, H-2d mAb alone, LPS + H-2d mAb, or LPS
priming and either control or Mirasol.
https://doi.org/10.1371/journal.pone.0178725.g005
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demonstrates Mirasol PRT treatment does not independently induce lung injury in a murine
model of TRALI. This finding is important for the development of safer and faster blood treat-
ment techniques to be used in places where they are urgently needed.
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